Top 10 Microspheres Companies

Why Microspheres Are Expanding?

The Global Microspheres Market reached an estimated USD 8.98 billion in 2025 and is projected to accelerate to USD 21.47 billion by 2035, expanding at a CAGR of 9.82% over the 2026--2035 forecast period. Two structural catalysts anchor this trajectory: the FDA's expanding approvals for yttrium-90 (Y-90) glass microspheres in interventional oncology, and a global push toward lightweight structural composites driven by electric-vehicle production mandates in the EU, China, and the United States.

Together, these forces convert what was once a niche specialty-materials category into a multi-vertical growth platform spanning medical technology, automotive, aerospace, and oil & gas applications. Global investment in injectable microsphere formulations alone surpassed USD 2.4 billion in combined R&D commitments between 2023 and 2025, reflecting pharma's confidence in drug-loaded microparticles as next-generation delivery vehicles.

The Microspheres Market is undergoing a technological shift from commodity filler beads to designed, application-specific controlled release microspheres and high-performance hollow glass bubbles. Glass remains the leading material, accounting for around 51% of 2026 revenue, owing to hollow glass bubbles for syntactic foams and targeted drug delivery particles. In 2026, hollow microspheres accounted for nearly 72% market share, owing to weight reduction regulations in automotive and aerospace applications.

By application, Medical technology dominated the market with a turnover of around USD 4.38 billion in 2026, driven by radioembolization techniques and injectable microsphere formulations. Automotive and aerospace composites together comprise the second largest application pocket. North America accounts for an estimated 37% of global revenue, due to interventional radiology reimbursement pathways and a well-established oil-and-gas services segment. Asia-Pacific is the fastest expanding area, at an estimated 12.78% CAGR.

What Structurally Separates Leaders from the Field?

MRFR identifies four structural factors that define category leadership in the Microspheres Market: proprietary materials science IP spanning glass-forming, polymer synthesis, and ceramic processing; regulatory validation depth enabling FDA-cleared Y-90 devices and pharmaceutical-grade PLGA encapsulation; integrated manufacturing-to-application engineering capabilities that convert raw materials into application-specific formulations; and scale-driven cost advantages in high-volume industrial grades that lock in automotive and construction sector contracts. Companies controlling pharmaceutical-grade Type I borosilicate tubing production --- where Schott and Nippon Electric Glass control over 70% of supply --- command structural pricing power that downstream assemblers cannot replicate.

Meanwhile, polymer innovators like Evonik (PLGA biodegradable polymer beads) and Nouryon (Expancel expandable microspheres) are winning formulation awards from top-20 pharmaceutical and coatings companies, positioning engineered polymers for 18--22% market share by 2032. The convergence of AI-optimized manufacturing, digital twin process modeling, and real-time particle-size monitoring is creating a next-generation competitive layer that will favor platform-integrated operators over commodity producers.

Top 10 Global Microspheres Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading microspheres companies globally, evaluated on the basis of revenue performance, geographic presence, materials science IP, regulatory validation depth, manufacturing scale, and application engineering capabilities. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026.

Detailed Company Profiles

1. 3M Company | NYSE: MMM | Saint Paul, Minnesota, USA

3M Company reported total net sales of USD 24.58 billion in FY2024, per its SEC Form 10-K filing, with its Safety & Industrial segment contributing approximately USD 10.9 billion. The company's microsphere portfolio spans the iM series hollow glass bubbles for syntactic foams and lightweight composites, retroreflective glass beads for road-safety markings, and precision solid microspheres for industrial and medical applications --- the broadest diversified microsphere offering globally.

3M's strategic moat lies in its vertically integrated glass production and materials science heritage: proprietary borosilicate glass-forming technology, advanced adhesive systems, and a 200+ country distribution network that no competitor can replicate.

2. Evonik Industries | Frankfurt: EVK | Essen, Germany

Evonik Industries reported total sales of EUR 14.07 billion in FY2025, per its Annual Report, with adjusted EBITDA of EUR 1.87 billion and an adjusted EBITDA margin of 13.3%. The company's strategic differentiation in the Microspheres Market is anchored in its RESOMER® portfolio of biodegradable polymer beads --- PLGA-based microspheres used in controlled-release drug delivery, tissue regeneration scaffolds, and long-acting injectable formulations.

In March 2020, Evonik expanded its Birmingham, Alabama CDMO facility with a state-of-the-art cGMP production line for clinical-stage injectable PLGA microspheres --- a capacity addition that positions Evonik as the leading outsourced manufacturer for pharmaceutical drug-loaded microparticles.

3. Trelleborg AB | Nasdaq Stockholm: TREL B | Trelleborg, Sweden

In Trelleborg AB’s Annual Report, net sales in FY2024 were SEK 34.17 billion (~USD 3.2 billion). EBITA excluding items impacting comparability was SEK 6,140 million, with an EBITA margin of 18.0%. The company’s strategic position in the Microspheres Market is based on its Trelleborg Industrial Solutions segment (~45% of revenue), which produces hollow glass and polymer microspheres for deepwater buoyancy modules, syntactic foams and marine/offshore applications – a niche where Trelleborg has a top-three position globally. In April 2024, Trelleborg divested Trelleborg Medical Solutions into a standalone business area (~SEK 2.9 billion, ~8% of revenue) with products in precision polymer molding for drug delivery systems, surgical tools, and biopharma applications --- a strategic pivot that fits well with the medical microsphere growth journey.

The acquisition of National Gummi AB in April 2025 expanded antivibration capabilities. In October 2025, Trelleborg Medical Solutions’ BioPharma Center of Excellence outside of Boston, Massachusetts, was expanded, showing aggressive investment in the U.S. healthcare microsphere and polymer component markets. Trelleborg’s commitment to cut Scope 1 and 2 CO2 emissions by 55% by 2024 and its ‘Polymers for Tomorrow’ sustainable materials programme mean its microsphere products are well positioned in an ESG-led procurement landscape.

4. Potters Industries (PQ Group) | Private (PQ Group subsidiary) | Malvern, Pennsylvania, USA

Potters Industries operates as a subsidiary of PQ Group, specializing in retroreflective glass beads, engineered solid microspheres, and precision-graded industrial glass beads for road-safety coatings, aerospace composites, and industrial fillers. The company's strategic moat is built on its road-safety market leadership: Potters' glass beads are specified in Federal Highway Administration (FHWA) minimum pavement marking retroreflectivity requirements and are embedded in the Safe Streets and Roads for All (SS4A) funding programs --- a regulatory-driven demand pipeline that provides multi-year revenue visibility.

Potters' microsphere product lines span solid glass beads for retroreflective road markings, hollow glass bubbles for lightweight composites, and specialty-coated microspheres for aerospace and automotive underbody shield applications.

5. Nouryon (formerly AkzoNobel Specialty Chemicals) | Private (Carlyle / GIC) | Amsterdam, Netherlands

Nouryon operates as a private company owned by Carlyle and GIC, following its 2018 carve-out from AkzoNobel, and is a global leader in specialty chemicals with operations in 80+ countries. The company's strategic differentiation in the Microspheres Market is anchored in its Expancel® brand of expandable microspheres --- thermoplastic microspheres that expand upon heating to create lightweight, closed-cell structures in coatings, plastics, inks, and construction materials.

Expancel® microspheres reduce product density by 30--50% while maintaining mechanical properties, making them essential additives for automotive interior panels, shoe soles, and packaging materials where weight reduction and material efficiency are critical. Nouryon's microsphere technology is protected by a deep patent portfolio covering expansion chemistry, shell composition, and particle-size distribution control --- an IP moat that has prevented meaningful generic competition for over two decades.

6. Chase Corporation | NYSE: CCF | Westwood, Massachusetts, USA

According to its SEC Form 10-K filing, Chase Corporation generated total revenue of approximately USD 404 million in FY2023, of which its specialty composites and microsphere-based materials represented an estimated USD 30–40 million. The company's strategic portfolio consists of industrial coatings, tapes, adhesives, sealants and microsphere-based protective products which are sold under the Dualite®, HumiSeal®, CIM® Industries and Chase Protective Coatings brands.® The Chase Dualite® microsphere product line is a family of hollow polymer microspheres used as lightweight fillers in coatings, adhesives and composites where density reduction and viscosity control are essential performance factors.

7. Mo-Sci Corporation | Private | Rolla, Missouri, USA

Mo-Sci Corporation is a private U.S.-based company specializing in bioactive glass microspheres, precision medical-grade glass and ceramic spheres, and radiotherapy beads --- with estimated annual revenue of USD 15--25 million. The company's strategic differentiation lies in its medical-technology pureplay focus: Mo-Sci manufactures bioactive glass microspheres for bone regeneration, wound healing, and dental applications, as well as precision Y-90 glass microspheres for interventional oncology radioembolization procedures. Mo-Sci's bioactive glass compositions --- based on proprietary formulations of silica, calcium, and phosphate --- are designed to bond with living tissue and stimulate osteogenesis, making them critical components in synthetic bone grafts and tissue engineering scaffolds.

8. Cospheric LLC | Private | Santa Barbara, California, USA

Cospheric LLC is a private U.S.-based company specializing in precision polymer and glass microspheres for research, calibration, and industrial applications --- a niche specialist with undisclosed revenue estimated at under USD 10 million annually. The company's strategic differentiation lies in its monodisperse microsphere capabilities: Cospheric produces highly uniform spherical particles with precise density matching, fluorescent labeling, and surface functionalization for applications in flow cytometry calibration, particle image velocimetry, and microfluidics research.

Cospheric's product catalog spans over 2,000 standard microsphere formulations across polymer, glass, ceramic, and metal compositions, with custom manufacturing services for researchers requiring bespoke particle sizes, densities, and surface chemistries. The company's customer base is concentrated in academic research institutions, pharmaceutical R&D laboratories, and industrial quality-control departments --- a market segment that values technical precision and batch-to-batch consistency over volume pricing.

9. Matsumoto Yushi-Seiyaku Co. | Private (Matsumoto Yushi Group) | Osaka, Japan

Matsumoto Yushi-Seiyaku is a private company from Japan and a member of the Matsumoto Yushi Group, which specializes in thermally expandable microspheres for lightweighting in coatings, plastics, and construction materials. The company’s strategic differentiator is its heat expansion technology: Matsumoto Yushi-Seiyaku microspheres consist of a thermoplastic shell containing a blowing agent which expands on heating to form closed cells and reduce the density of the material by 20-40% without loss of mechanical strength.

The company’s microspheres are used extensively in automobile interior trim, footwear midsoles, packaging materials and wallpaper --- areas where weight reduction, insulation and tactile qualities are important. Matsumoto Yushi-Seiyaku’s solid Asia-Pacific manufacturing presence and ties with Japanese car OEMs (Toyota, Honda, Nissan) provide it with a locked-in demand pipeline, shielding it from price competition in global commodity microsphere markets.

10. Sinosteel Maanshan New Material | State-Owned Enterprise | Maanshan, China

Sinosteel Maanshan New Material is a state-owned Chinese enterprise specializing in fly ash cenospheres, hollow glass microspheres, and industrial filler materials for construction, oilfield drilling fluids, and coatings applications. The company's strategic positioning is anchored in cost advantage: as a state-owned enterprise with access to low-cost raw materials, government-backed capacity expansion, and domestic Chinese demand, Sinosteel Maanshan produces hollow microspheres at price points 30--40% below Western competitors for equivalent industrial grades.

The company's product portfolio spans fly ash cenospheres (byproducts of coal combustion), synthetically produced hollow glass microspheres, and surface-treated microspheres for oilfield cementing and drilling fluid weight reduction.

M&A Activity Tracker (2020--2025)

The Microspheres Market has experienced targeted consolidation as materials science companies and pharmaceutical CDMOs pursued inorganic growth to capture the converging medical technology, automotive lightweighting, and pharmaceutical controlled-release segments. Market Research Future tracks the following verified, named transactions directly relevant to the microspheres market.

Key Trend: MRFR analysis identifies vertical integration of materials science IP with application-specific formulation capabilities as the dominant competitive dynamic in the Microspheres Market. Evonik's Birmingham cGMP facility expansion and Trelleborg's Medical Solutions carve-out demonstrate that pharmaceutical-grade microsphere manufacturing is consolidating into platform CDMOs with integrated regulatory, formulation, and manufacturing capabilities. Conversely, industrial microspheres --- particularly hollow glass bubbles and expandable microspheres --- are facing commoditization pressure from Chinese state-backed producers (Sinosteel Maanshan) and overcapacity in construction-grade fillers. By 2030, MRFR projects that platform operators combining proprietary materials synthesis, cGMP manufacturing, and regulatory dossier depth under one entity will capture 55--60% of pharmaceutical microsphere revenue, up from under 40% today, while industrial microsphere margins will compress by 15--20% as Chinese capacity floods export markets.

R&D Investment & Innovation Signals

• 3M's Safety & Industrial segment operating income rose 7.2% to USD 2.5 billion in FY2024, while the company maintained 7.7 billion in cash and marketable securities --- a financial position that supports continued investment in glass microsphere R&D and potential acquisition of emerging microsphere technology platforms as the company executes its PFAS manufacturing exit by end-2025.

• Evonik's Birmingham, Alabama CDMO facility expansion --- opened in March 2020 --- added state-of-the-art cGMP capacity for clinical-stage injectable PLGA microspheres, positioning Evonik as the leading outsourced manufacturer for pharmaceutical drug-loaded microparticles and creating a capacity moat that emerging competitors cannot replicate without 3--5 year capital investment timelines.

• Trelleborg established Trelleborg Medical Solutions as a standalone business area in April 2024 (~SEK 2.9 billion, ~8% of revenue) and expanded its BioPharma Center of Excellence near Boston, Massachusetts in October 2025 --- a strategic pivot toward pharmaceutical polymer microspheres that signals intent to capture high-margin medical-technology demand but requires further scaling to challenge Evonik's RESOMER® franchise.

• The FDA granted premarket approval (PMA) to TheraSphere Y-90 glass microspheres in March 2021 for hepatocellular carcinoma treatment --- expanding targeted internal radiation therapy options and validating the clinical utility of radiotherapy microspheres; this regulatory milestone has driven a 15--20% annual growth rate in interventional oncology microsphere procedures and created a premium pricing environment for medical-grade glass microspheres.

• The European Chemicals Agency (ECHA) formally adopted the REACH restriction on intentionally added microplastics in September 2023 --- a regulatory milestone that is accelerating demand for biodegradable polymer beads (Evonik RESOMER®, PLA-based alternatives) and glass microspheres as replacements for polyethylene microbeads in cosmetics, coatings, and detergents across European markets.